| Specialty Retail Industry | Consumer Discretionary Sector | Mr. Guo Gang Zheng CEO | XSHE Exchange | CNE100003GC2 ISIN |
| CN Country | 1,275 Employees | 22 Jun 2026 Last Dividend | 19 May 2023 Last Split | - IPO Date |
Zhejiang AngLiKang Pharmaceutical CO.,LTD. is a reputable pharmaceutical company based in Shengzhou, China. Since its foundation in 2001, the company has actively engaged in the manufacture of Active Pharmaceutical Ingredients (APIs) and a wide range of pharmaceutical preparations. Specializing in oral cephalosporins, the company has expanded its expertise to cover vital healthcare areas such as cardiovascular and kidney diseases. The breadth of its commitment to improving health care is evident through its diverse product offerings targeting critical therapeutic areas including anti-infection, antihypertensive, digestive, central nervous system diseases, and respiratory preparations.
Specialized in the development and manufacturing of cephalosporin-based antibiotics, Zhejiang AngLiKang Pharmaceutical provides a broad spectrum of oral cephalosporin medications. These are critical in treating infections caused by bacteria resistant to other antibiotics, showcasing the company's commitment to combating antimicrobial resistance.
The company offers an extensive range of products for the treatment and management of cardiovascular diseases. These preparations are formulated to address a wide variety of conditions related to heart and blood vessels, emphasizing the company's role in supporting heart health.
Zhejiang AngLiKang Pharmaceutical extends its pharmaceutical expertise to include treatments for kidney diseases. These products are designed to help manage and treat various kidney conditions, underscoring the company's dedication to contributing to nephrology.
In addition to oral cephalosporins, the company produces a comprehensive array of products aimed at preventing and treating infectious diseases. Through these products, Zhejiang AngLiKang Pharmaceutical reinforces its commitment to safeguarding public health against infections.
Addressing the global challenge of hypertension, the company provides a variety of antihypertensive medications. These products are crucial for managing high blood pressure, further indicating the company's involvement in promoting cardiovascular health.
Focused on enhancing gastrointestinal health, Zhejiang AngLiKang Pharmaceutical offers treatments for a range of digestive system conditions. These medications help in improving digestive health and quality of life for individuals suffering from various gastrointestinal disorders.
Understanding the impact of central nervous system disorders, the company provides medications aimed at treating and managing these conditions. This aspect of their product line demonstrates Zhejiang AngLiKang Pharmaceutical’s dedication to addressing mental health and neurological diseases.
The respiratory system is another primary focus for Zhejiang AngLiKang Pharmaceutical. The company offers a selection of preparations for respiratory conditions, aiding in the treatment and management of diseases affecting the respiratory tract.